Fig 1: Role of FNDC5/irisin in exercise-induced protection against bone loss in OVX-induced mice. A-I Schematic flow diagram representing the OVX-mice subjected to sedentary, treadmill, with or without AAV9-shFNDC5 (n = 6). Briefly, OVX-mice were randomly subjected to sedentary and AAV9-shCtrl (Sed + AAV9-shCtrl group, n = 6), eight weeks treadmill training and AAV9-shCtrl (Exe + AAV9-shCtrl group, n = 6), or eight weeks treadmill training and AAV9-shFNDC5 (Exe + AAV9-shFNDC5 group, n = 6). B Representative views of micro-CT were shown. C Statistical analysis of mineral density BMD. D Statistical analysis of Tb.BV/TV. E Statistical analysis of Tb.N. F Statistical analysis of Tb.Th. G Statistical analysis of Tb.Sp. H Quantification of Ct.Th. I Representative images of calcein double labeling. Scale bar represents 100 μm. Quantitative analysis of BFR and MAR was shown in the right panel. J Representative immunohistochemical images of OCN in bone tissues. Scale bar represents 200 μm. Quantitative analysis of OCN positive area was presented in the right panel. Results are represented by mean ± SD with six replications (in vivo) per group. Statistical significance was determined using two-way ANOVA with the Tukey’s HSD post hoc analysis. *p < 0.05. **p < 0.01. ***p < 0.001. NS, no significance
Fig 2: Levels of FNDC5/irisin in circulation of exercise rats and roles of irisin in sEVs-induced promotion of bone formation. A Levels of serum FNDC5/irisin in rats was detected by commercial ELISA kit (n = 6). B Level of FNDC5/irisin in sEVs was detected by a commercial ELISA kit (n = 6). C-H BM-MSCs were incubated with Exe-sEVs or Sed-sEVs for the indicated time and the cell lysates were isolated. C qRT-PCR was used to detect mRNA expression of FNDC5 in BM-MSCs (n = 4). D Western blotting was used to detect protein expression of FNDC5 in BM-MSCs (n = 4). Quantitative analysis was shown in the right panel, as shown by percentage relative to the control group (100%). E BM-MSCs were treated with serum isolated from Sed-mice or Exe-mice with or without deletion of sEVs by ultracentrifuging. After the treatment, western blotting was used to detect protein expression of FNDC5 in BM-MSCs. Quantitative analysis was shown in the right panel. F–H BM-MSCs were incubated with Exe-sEVs or Sed-sEVs with or without FNDC5 neutralization antibodies. F Expression of Runx2 was detected by western blotting (n = 4). Quantitative analysis was shown in the right panel. G ALP activity was determined by a specific ALP measurement kit (n = 5). H The osteogenic differentiation and mineralization level of BM-MSCs was assessed by ARS and ALP staining (n = 5). Scale bar represents 200 μm. Quantitative analysis was presented in the right panel. Results are represented by mean ± SD with four or five replicates per group. Statistical significance was determined using Student’s t-test. *p < 0.05. **p < 0.01. ***p < 0.001
Fig 3: Aptamer-modified FNDC5-sEVs effectively alleviated bone loss in OVX-induced mice. A Schematic illustration of the bone targeting aptamer-modified sEVs. B Rd-sEVs or Apt-sEVs, either with or without the aptamer modification, were labeled with DiR and subsequently administered intravenously to mice (100 μg per mouse, n = 4 per group). Representative ex-vivo images of major organs (B, left panel), and ex-vivo images of bone tissues (B, middle panel) were captured at 6 and 12 h post-treatment. Quantitative analysis was presented in the right panel. C-J OVX-mice were randomly assigned to receive intravenous injections of Rd-Ctrl-sEVs, Apt-Ctrl-sEVs, Rd-FNDC5-sEVs, or Apt-FNDC5-sEVs (100 μg per mouse) every three days for a duration of eight weeks. C Representative views of micro-CT were displayed. D Statistical analysis of BMD. E Statistical analysis of Tb.BV/TV. F Statistical analysis of Tb.N. G Statistical analysis of Tb.Th. H Statistical analysis of Tb.Sp. I Quantification of Ct.Th. J Representative images of calcein double labeling. Scale bar represents 100 μm. Quantitative analysis of BFR and MAR was presented in the right panel. K Representative immunohistochemical images of OCN in bone tissues. Quantitative analysis was presented in the right panel. Scale bar represents 200 μm. L Serum level of P1NP in mice was detected by ELISA kit. Results are represented by mean ± SD with six replications (in vivo) per group. Statistical significance was determined using Student’s t-test. *p < 0.05. **p < 0.01. ***p < 0.001. NS, no significance
Fig 4: FNDC5/irisin increased osteogenesis and decreased adipogenesis in BM-MSCs and promoted osteogenesis in vitro and in vivo. A-C BM-MSCs were incubated with irisin at concentration of 5 nM to 40 nM or vehicle control, accompanying with osteogenic medium. A The ALP activity was determined by a specific ALP measurement kit (n = 5). B The osteogenic differentiation and mineralization level of BM-MSCs was detected by ARS and ALP staining (n = 5). Scale bar represents 200 μm. C Expression of Runx2 was detected by western blotting (n = 4). D BM-MSCs were incubated with irisin at concentration of 5 nM to 40 nM or vehicle control, accompanying with adipogenic medium. Expression of PPARγ was detected by western blotting. E Lentivirus carrying FNDC5 was used to over-express FNDC5 in BM-MSCs, and then these cells loading on beta-tricalcium phosphate stent complex scaffold were implanted into nude mice for 12 weeks. F H&E staining of the isolated tissues. G Osteoid tissue formation was detected by Masson’s trichome staining. Quantitative analysis was shown in the right panel. H Representative immunohistochemical images of OCN, Runx2 and β-arrestin-2 in isolated tissues. I Cartilaginous tissue was detected by safranin O-fast green staining. Quantitative analysis was shown in the right panel. Green scale bar represents 1 mm. Red scale bar represents 400 μm. Black scale bar represents 100 μm. Quantitative analysis was shown in the right panel. Results are represented by mean ± SD with four or five replicates per group. Statistical significance was determined using Student’s t-test or two-way ANOVA with the Tukey’s HSD post hoc analysis. *p < 0.05. **p < 0.01. ***p < 0.001. NS, no significance
Fig 5: β-arrestin-2 mediated FNDC5/irisin-induced activation of p38MAPK and JNK and promoting effects on BM-MSCs osteogenic differentiation. A-E BM-MSCs were pretreated with β-arrestin-2 specific siRNA (si-β-arrestin-2) or control siRNA, and then incubated with irisin for indicated time, accompanying by osteogenic medium. A Expression of Runx2 and β-arrestin-2 was assessed by western blotting (n = 4). Quantitative analysis was shown in the right panel. B p-p38MAPK and p-JNK as well as their total proteins were detected by western blotting (n = 4). Quantitative analysis was shown in the right panel. C The ALP activity was assessed by a specific ALP measurement kit (n = 5). D The osteogenic differentiation and mineralization level of BM-MSCs was assessed by ARS and ALP staining (n = 5). Scale bar represents 200 μm. E BM-MSCs were pretreated with si-β-arrestin-2 or control siRNA, and then incubated with FNDC5/irisin for indicated time, accompanying by adipogenic medium. Expression of PPARγ was detected by western blotting (n = 4). Quantitative analysis was presented in the lower panel. Results are presented by mean ± SD with four or five replicates per group. Statistical significance was determined using Student’s t-test or two-way ANOVA with the Tukey’s HSD post hoc analysis. *p < 0.05. **p < 0.01. ***p < 0.001. NS, no significance
Supplier Page from CUSABIO Technology LLC for Rat Fibronectin type III domain-containing protein 5(FNDC5) ELISA Kit